EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort

Yuanchu J Yang iD, Chenjie Zeng iD, Kerry R Schaffer, Tam C Tran, Peter J Sauer, Lincoln A Brown, Ben H Park, Joshua C Denny

The Prostate · 2025

DOI: 10.1002/pros.24913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Yuanchu J Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cardiovascular Diseases, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research was supported by the National Human Genome Research Institute., Intramural NIH HHS, National Human Genome Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hormone therapy (HT) has greatly improved overall survival for prostate cancer patients, but may also influence cardiovascular health in an already high‐risk population.

Methods

This retrospective cohort study examined participants in the All of Us Research Program with prostate cancer, had no prior history of adverse cardiovascular events, and were either treated or not treated with HT. HT was defined as GnRH agonists, GnRH antagonists, abiraterone, androgen antagonists, or androgen receptor pathway inhibitors. We defined adverse cardiovascular event as myocardial infarctions, heart failure, or strokes. Time to adverse cardiovascular event was defined using longitudinal electronic health record data. We evaluated whether HT use affected the risk of adverse cardiovascular events using a Cox regression model adjusted for established cardiovascular risk factors.

Results

The final cohort included 5156 participants. After adjustment for cardiovascular risk covariates, HT treatment was associated with increased risk of adverse cardiovascular event (HR: 1.22; 95% CI: 1.01–1.48; p = 0.03). In participants with pre‐treatment dyslipidemia, HT usage was associated with increased risk of adverse cardiovascular events (HR: 1.52; 95% CI: 1.19–1.95; p < 0.001). In participants without pre‐treatment dyslipidemia, no association was found (HR: 0.96; 95% CI: 0.71–1.30; p = 0.81).

Conclusions

Our results show that HT‐associated cardiovascular risk may be synergistically amplified by dyslipidemia. These results suggest that risk stratification by dyslipidemia status may improve cardiovascular outcomes for prostate cancer survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCardiovascular DiseasesAntineoplastic Agents, HormonalHumansMaleRetrospective StudiesAgedMiddle AgedAndrogen AntagonistsUnited StatesCohort Studies

Stichwörter der Autor:innen

cardio‐oncologyhormone therapyoutcomesprostate cancer

Substanzen

Androgen AntagonistsAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Precision Health Informatics Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Academic Internship Program, National Institutes of Health, Bethesda, Maryland, USA.
  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Yuanchu J Yang, Chenjie Zeng

Förderung

  • This research was supported by the National Human Genome Research Institute.
  • Intramural NIH HHS
  • National Human Genome Research Institute

Zitieren

APA

Yang, Y. J., Zeng, C., Schaffer, K. R., Tran, T. C., Sauer, P. J., Brown, L. A., Park, B. H., & Denny, J. C. (2025). Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort. The Prostate. https://doi.org/10.1002/pros.24913

Vancouver

Yang YJ, Zeng C, Schaffer KR, Tran TC, Sauer PJ, Brown LA, et al. Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort. The Prostate. 2025. doi:10.1002/pros.24913

BibTeX
@article{Yang2025,
  author = {Yang, Yuanchu J and Zeng, Chenjie and Schaffer, Kerry R and Tran, Tam C and Sauer, Peter J and Brown, Lincoln A and Park, Ben H and Denny, Joshua C},
  title = {Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24913}
}
Kostenlos starten →